Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
CONCLUSIONS: We present here an assay suitable for the simultaneous measurement of serum levels of all third generation AIs and ultralow levels of estrogens, providing a powerful new tool to study drug efficacy and compliance. The method is highly valuable for postmenopausal patients whose pretreatment estradiol levels are below threshold of detection for most routine assays, but still require suppression.PMID:34958096 | DOI:10.1210/clinem/dgab923 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 27, 2021 Category: Cancer & Oncology Authors: Bj ørn-Erik Bertelsen Kristin Viste Thomas Helland Magnus Hagland H åvard Søiland J ürgen Geisler Tone Hoel Lende Per Eystein L ønning J ørn V Sagen Gunnar Mellgren Bj ørg Almås Source Type: research
Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
CONCLUSIONS: We present here an assay suitable for the simultaneous measurement of serum levels of all third generation AIs and ultralow levels of estrogens, providing a powerful new tool to study drug efficacy and compliance. The method is highly valuable for postmenopausal patients whose pretreatment estradiol levels are below threshold of detection for most routine assays, but still require suppression.PMID:34958096 | DOI:10.1210/clinem/dgab923 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - December 27, 2021 Category: Cancer & Oncology Authors: Bj ørn-Erik Bertelsen Kristin Viste Thomas Helland Magnus Hagland H åvard Søiland J ürgen Geisler Tone Hoel Lende Per Eystein L ønning J ørn V Sagen Gunnar Mellgren Bj ørg Almås Source Type: research
Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
CONCLUSIONS: We present here an assay suitable for the simultaneous measurement of serum levels of all third generation AIs and ultralow levels of estrogens, providing a powerful new tool to study drug efficacy and compliance. The method is highly valuable for postmenopausal patients whose pretreatment estradiol levels are below threshold of detection for most routine assays, but still require suppression.PMID:34958096 | DOI:10.1210/clinem/dgab923 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - December 27, 2021 Category: Endocrinology Authors: Bj ørn-Erik Bertelsen Kristin Viste Thomas Helland Magnus Hagland H åvard Søiland J ürgen Geisler Tone Hoel Lende Per Eystein L ønning J ørn V Sagen Gunnar Mellgren Bj ørg Almås Source Type: research
Should Skeletal Maturation Be Manipulated for Extra Height Gain?
Skeletal maturation can be delayed by reducing the exposure to estrogens, either by halting pubertal development through administering a GnRH analogue (GnRHa), or by blocking the conversion of androgens to estrogens through an aromatase inhibitor (AI). These agents have been investigated in children with growth disorders (off-label), either alone or in combination with recombinant human growth hormone (rhGH). GnRHa is effective in attaining a normal adult height (AH) in the treatment of children with central precocious puberty, but its effect in short children with normal timing of puberty is equivocal. If rhGH-treated chi...
Source: Frontiers in Endocrinology - December 16, 2021 Category: Endocrinology Source Type: research
A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222
CONCLUSION: Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer. Prognostic impact of baseline ctDNA and copy number variations in CTC was demonstrated.PMID:34844978 | DOI:10.1158/1078-0432.CCR-21-3131 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - November 30, 2021 Category: Cancer & Oncology Authors: Halle C F Moore William E Barlow George Somlo Julie R Gralow Anne F Schott Daniel F Hayes Peter Kuhn James B Hicks Lisa Welter Philip A Dy Christina H Yeon Alison K Conlin Ernie Balcueva Danika L Lew Debasish Tripathy Lajos Pusztai Gabriel N Hortobagyi Source Type: research
A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222
CONCLUSION: Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer. Prognostic impact of baseline ctDNA and copy number variations in CTC was demonstrated.PMID:34844978 | DOI:10.1158/1078-0432.CCR-21-3131 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 30, 2021 Category: Cancer & Oncology Authors: Halle C F Moore William E Barlow George Somlo Julie R Gralow Anne F Schott Daniel F Hayes Peter Kuhn James B Hicks Lisa Welter Philip A Dy Christina H Yeon Alison K Conlin Ernie Balcueva Danika L Lew Debasish Tripathy Lajos Pusztai Gabriel N Hortobagyi Source Type: research
A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222
CONCLUSION: Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer. Prognostic impact of baseline ctDNA and copy number variations in CTC was demonstrated.PMID:34844978 | DOI:10.1158/1078-0432.CCR-21-3131 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - November 30, 2021 Category: Cancer & Oncology Authors: Halle C F Moore William E Barlow George Somlo Julie R Gralow Anne F Schott Daniel F Hayes Peter Kuhn James B Hicks Lisa Welter Philip A Dy Christina H Yeon Alison K Conlin Ernie Balcueva Danika L Lew Debasish Tripathy Lajos Pusztai Gabriel N Hortobagyi Source Type: research
A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222
CONCLUSION: Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer. Prognostic impact of baseline ctDNA and copy number variations in CTC was demonstrated.PMID:34844978 | DOI:10.1158/1078-0432.CCR-21-3131 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - November 30, 2021 Category: Cancer & Oncology Authors: Halle C F Moore William E Barlow George Somlo Julie R Gralow Anne F Schott Daniel F Hayes Peter Kuhn James B Hicks Lisa Welter Philip A Dy Christina H Yeon Alison K Conlin Ernie Balcueva Danika L Lew Debasish Tripathy Lajos Pusztai Gabriel N Hortobagyi Source Type: research
A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222
CONCLUSION: Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer. Prognostic impact of baseline ctDNA and copy number variations in CTC was demonstrated.PMID:34844978 | DOI:10.1158/1078-0432.CCR-21-3131 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 30, 2021 Category: Cancer & Oncology Authors: Halle C F Moore William E Barlow George Somlo Julie R Gralow Anne F Schott Daniel F Hayes Peter Kuhn James B Hicks Lisa Welter Philip A Dy Christina H Yeon Alison K Conlin Ernie Balcueva Danika L Lew Debasish Tripathy Lajos Pusztai Gabriel N Hortobagyi Source Type: research
A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222
CONCLUSION: Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer. Prognostic impact of baseline ctDNA and copy number variations in CTC was demonstrated.PMID:34844978 | DOI:10.1158/1078-0432.CCR-21-3131 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - November 30, 2021 Category: Cancer & Oncology Authors: Halle C F Moore William E Barlow George Somlo Julie R Gralow Anne F Schott Daniel F Hayes Peter Kuhn James B Hicks Lisa Welter Philip A Dy Christina H Yeon Alison K Conlin Ernie Balcueva Danika L Lew Debasish Tripathy Lajos Pusztai Gabriel N Hortobagyi Source Type: research
A Case of Multiple Liver Metastases after Surgery in Elderly HER2-Positive Breast Cancer in Which Anastrozole + Trastuzumab Was Ineffective but T-DM1 Was Effective
Chemotherapy is often difficult to treat human epidermal growth factor receptor 2 (HER2)-positive metastatic recurrent breast cancer in the elderly, and no standard treatment has been established at this point. We experienced a case in which trastuzumab (Tmab) + anastrozole (ANA) was ineffective (progressive disease; PD) in elderly HER2-positive breast cancer with postoperative multiple liver metastases, but T-DM1 was significantly effective (complete response; CR), and treatment could be continued safely. An 82-year-old woman was referred to our department with a right breast mass. A close examination revealed right breas...
Source: Case Reports in Oncology - November 15, 2021 Category: Cancer & Oncology Source Type: research
Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients
ConclusionsAddition of an aromatase inhibitor (ANA) to the dopamine agonist therapy improved the control of prolactin levels and induced tumour regression. (Source: Pituitary)
Source: Pituitary - November 7, 2021 Category: Endocrinology Source Type: research
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
CONCLUSIONS: Consistent with findings in the overall population, abemaciclib plus NSAI was an effective initial treatment in the Japanese subpopulation, with a manageable safety profile.CLINICAL TRIAL REGISTRATION: NCT02246621; U.S. National Library of Medicine: https://clinicaltrials.gov/ct2/show/NCT02246621 .PMID:34661821 | DOI:10.1007/s12282-021-01295-0 (Source: Breast Cancer)
Source: Breast Cancer - October 18, 2021 Category: Cancer & Oncology Authors: Masato Takahashi Eriko Tokunaga Joji Mori Yoshinori Tanizawa Jan-Stefan van der Walt Tsutomu Kawaguchi Matthew P Goetz Masakazu Toi Source Type: research
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
CONCLUSIONS: Consistent with findings in the overall population, abemaciclib plus NSAI was an effective initial treatment in the Japanese subpopulation, with a manageable safety profile.CLINICAL TRIAL REGISTRATION: NCT02246621; U.S. National Library of Medicine: https://clinicaltrials.gov/ct2/show/NCT02246621 .PMID:34661821 | DOI:10.1007/s12282-021-01295-0 (Source: Breast Cancer)
Source: Breast Cancer - October 18, 2021 Category: Cancer & Oncology Authors: Masato Takahashi Eriko Tokunaga Joji Mori Yoshinori Tanizawa Jan-Stefan van der Walt Tsutomu Kawaguchi Matthew P Goetz Masakazu Toi Source Type: research
"novel mechanisms targeted by drug trials in pulmonary arterial hypertension"
Chest. 2021 Oct 13:S0012-3692(21)04093-9. doi: 10.1016/j.chest.2021.10.010. Online ahead of print.ABSTRACTPulmonary arterial hypertension (PAH) is a rare disease associated with abnormally elevated pulmonary pressures and right heart failure resulting in high morbidity and mortality. While PAH prognosis has improved with the introduction of pulmonary vasodilators, disease progression remains a major problem. Given that available therapies are inadequate for preventing small vessel loss and obstruction, there is an active interest in identifying drugs capable of targeting angiogenesis and mechanisms involved in regulation o...
Source: Chest - October 16, 2021 Category: Respiratory Medicine Authors: David F Condon Stuti Agarwal Ananya Chakraborty Natasha Auer Rocio Vazquez Hiral Patel Roham T Zamanian Vinicio A de Jesus Perez David F Condon Source Type: research
